Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S

Open source

DOI: 10.1093/oncolo/oyaf048
Published: 2025 May 8
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyaf048,
  title = {Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.},
  author = {Ueno NT and Cottone F and Dunton K and Jacot W and Yamashita T and Sohn J and Tokunaga E and Prat A and Tsurutani J and Park YH and Rugo HS and Xu B and Cardoso F and Mitri Z and Mahtani R and Aguilar CO and Xiao F and Harbeck N and Cameron DA and Modi S},
  year = {2025},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyaf048},
  url = {https://doi.org/10.1093/oncolo/oyaf048}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
AU  - Ueno NT
AU  - Cottone F
AU  - Dunton K
AU  - Jacot W
AU  - Yamashita T
AU  - Sohn J
AU  - Tokunaga E
AU  - Prat A
AU  - Tsurutani J
AU  - Park YH
AU  - Rugo HS
AU  - Xu B
AU  - Cardoso F
AU  - Mitri Z
AU  - Mahtani R
AU  - Aguilar CO
AU  - Xiao F
AU  - Harbeck N
AU  - Cameron DA
AU  - Modi S
PY  - 2025
JO  - The oncologist
DO  - 10.1093/oncolo/oyaf048
UR  - https://doi.org/10.1093/oncolo/oyaf048
ER  -

APA

NT, U., F, C., K, D., W, J., T, Y., J, S., E, T., A, P., J, T., YH, P., HS, R., B, X., F, C., Z, M., R, M., CO, A., F, X., N, H., DA, C., & S, M. (2025). Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.. The oncologist. https://doi.org/10.1093/oncolo/oyaf048

Source records

pubmed · retrieved 2026-09-25T16:20:53.050Z
europe-pmc · retrieved 2026-09-25T16:20:53.065Z